Dixon Hubard Feinour & Brown Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CVS Health
CVS
|
+$8.17M |
| 2 |
Trimble
TRMB
|
+$7.43M |
| 3 |
NVIDIA
NVDA
|
+$7.09M |
| 4 |
Vanguard Short-Term Bond ETF
BSV
|
+$6.37M |
| 5 |
iShares MBS ETF
MBB
|
+$6.33M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$32.7M |
| 2 |
Microsoft
MSFT
|
+$25.9M |
| 3 |
lululemon athletica
LULU
|
+$19.8M |
| 4 |
Veeva Systems
VEEV
|
+$17.6M |
| 5 |
Thermo Fisher Scientific
TMO
|
+$14.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 22.74% |
| 2 | Healthcare | 19.11% |
| 3 | Consumer Discretionary | 9.45% |
| 4 | Financials | 7.79% |
| 5 | Consumer Staples | 6.71% |
Similar funds
Dixon Hubard Feinour & Brown's Q2 2021 Portfolio in Review
As of Q2 2021, Dixon Hubard Feinour & Brown held 227 positions worth $481M, down 41% from $812M the previous quarter. Its ten largest holdings account for 34% of the portfolio.
Dixon Hubard Feinour & Brown withdrew a net $439M in Q2 2021, closing 42 positions and reducing 145 holdings. Its most notable exit was Netflix, an estimated $14.9M position sold in full.
By sector, the portfolio is most concentrated in Technology at 23% of assets, up from 22% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, Dixon Hubard Feinour & Brown opened a new position in CVS Health worth $8.32M.
- Dixon Hubard Feinour & Brown's largest Q2 2021 buy was CVS Health: 99,762 shares worth $8.32M.
- Dixon Hubard Feinour & Brown added most to NVIDIA in Q2 2021, an estimated $7.09M increase.
- Dixon Hubard Feinour & Brown's biggest Q2 2021 reduction was Apple, cutting an estimated $32.7M.
- Dixon Hubard Feinour & Brown fully exited Netflix in Q2 2021, selling an estimated $14.9M.
- Dixon Hubard Feinour & Brown's ten largest holdings make up 34% of its $481M portfolio in Q2 2021.
- Dixon Hubard Feinour & Brown opened 22 new positions and closed 42 in Q2 2021.
- Dixon Hubard Feinour & Brown's portfolio value fell 41% quarter-over-quarter to $481M.
Based on Dixon Hubard Feinour & Brown's 13F filing for Q2 2021, filed 23 Aug 2021.